0000899243-17-011489.txt : 20170502 0000899243-17-011489.hdr.sgml : 20170502 20170502174836 ACCESSION NUMBER: 0000899243-17-011489 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20170429 FILED AS OF DATE: 20170502 DATE AS OF CHANGE: 20170502 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CTI BIOPHARMA CORP CENTRAL INDEX KEY: 0000891293 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 911533912 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3101 WESTERN AVENUE STREET 2: SUITE 600 CITY: SEATTLE STATE: WA ZIP: 98121 BUSINESS PHONE: 2062827100 MAIL ADDRESS: STREET 1: 3101 WESTERN AVENUE STREET 2: SUITE 600 CITY: SEATTLE STATE: WA ZIP: 98121 FORMER COMPANY: FORMER CONFORMED NAME: CELL THERAPEUTICS INC DATE OF NAME CHANGE: 19960321 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LOVE RICHARD L CENTRAL INDEX KEY: 0001201041 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-28386 FILM NUMBER: 17806436 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2017-04-29 0 0000891293 CTI BIOPHARMA CORP CTIC 0001201041 LOVE RICHARD L 3101 WESTERN AVENUE, SUITE 600 SEATTLE WA 98121 1 0 0 0 Common Stock 2017-04-29 4 M 0 34736 A 88318 D Restricted Stock Unit 2017-04-29 4 M 0 34736 0.00 D Common Stock 34736 0 D CTIC completed a 1-for-10 reverse stock split in January 2017. All share amounts reported in this Form 4 have been retroactively adjusted to reflect this stock split. Each restricted stock unit represents the right to receive, at settlement, one share of CTIC common stock. This transaction represents the settlement of restricted stock units in shares of common stock on their scheduled vesting date. This restricted stock unit was granted on April 29, 2016 and vested on April 29, 2017. Exhibit List: Exhibit 24 -- Power of Attorney /s/ Bruce J. Seeley, as Attorney-in-Fact for Richard L. Love 2017-04-29 EX-24 2 attachment1.htm EX-24 DOCUMENT

                                POWER OF ATTORNEY

                  FOR SEC FILINGS ON FORMS ID, 3, 4, 5 AND 144
                           IN RESPECT OF SECURITIES OF
                               CTI BIOPHARMA CORP.

                The undersigned hereby constitutes and appoints each of
Adam R. Craig and Bruce J. Seeley as his true and lawful attorney-in-fact and
agent, with full power of substitution and resubstitution for him in his name
and stead in any and all capacities, to sign and file for and on his behalf, in
respect of any acquisition, disposition or other change in ownership of any
Common Stock of CTI BioPharma Corp. (the "Company"), the following:

        (i)     any Form ID to be filed with the Securities and Exchange
                Commission (the "SEC");

        (ii)    any Initial Statement of Beneficial Ownership of Securities on
                Form 3 to be filed with the SEC;

        (iii)   any Statement of Changes of Beneficial Ownership of Securities
                on Form 4 to be filed with the SEC;

        (iv)    any Annual Statement of Beneficial Ownership of Securities on
                Form 5 to be filed with the SEC;

        (v)     any Notice of Proposed Sale of Securities on Form 144 to be
                filed with the SEC; and

        (vi)    any and all agreements, certificates, receipts, or other
                documents in connection therewith.

                The undersigned hereby gives full power and authority to the
attorney-in-fact to seek and obtain as the undersigned's representative and on
the undersigned's behalf, information on transactions in the Company's
securities from any third party, including brokers, employee benefit plan
administrators and trustees, and the undersigned hereby authorizes any such
person to release such information to the undersigned and approves and ratifies
any such release of information.

                The undersigned hereby grants unto such attorney-in-fact and
agent full power and authority to do and perform each and every act and thing
requisite and necessary in connection with such matters and hereby ratifies and
confirms all that any such attorney-in-fact and agent or substitute may do or
cause to be done by virtue hereof.

                The undersigned acknowledges that:

        (i)     neither the Company nor such attorney-in-fact assumes (i) any
                liability for the undersigned's responsibility to comply with
                the requirement of the Securities Exchange Act of 1934, as
                amended (the "Exchange Act"), (ii) any liability of the
                undersigned for any failure to comply with such requirements or
                (iii) any obligation or liability of the undersigned for profit
                disgorgement under Section 16(b) of the Exchange Act; and

        (ii)    this Power of Attorney does not relieve the undersigned from
                responsibility for compliance with the undersigned's obligations
                under the Exchange Act, including without limitation the
                reporting requirements under Section 16 of the Exchange Act.

                This Power of Attorney shall remain in full force and effect
until revoked by the undersigned in a signed writing delivered to such
attorney-in-fact.

                IN WITNESS WHEREOF, the undersigned has executed this Power of
Attorney.

Date:  April 28, 2017
                                        /s/ Richard L. Love
                                        ---------------------------------------
                                        Richard L. Love